



Miltenyi Biotec



Generation of tumor-reactive T cells

CliniMACS Prodigy® Tumor Reactive T Cell Process

Application

Fully automated stimulation, labelling, enrichment, activation, transduction, and expansion of human T cells from patient material (either derived from tumor or via leukapheresis) for the production of tumor-reactive T cells.

This application sheet gives an overview of the specifications and materials required to perform the Tumor Reactive T Cell (TRT) Process on the CliniMACS Prodigy. In addition, it illustrates the process workflow and tubing set configuration, and provides performance data of our own in-house results.

Specifications

Process name:	Tumor Reactive T Cell Process
Starting cell number for stimulation/selection:	Tumor digest: up to $2-4 \times 10^8$ Leukapheresis: up to 1×10^9
Starting cell number for expansion:	Up to 1×10^7 (recommended 1×10^6)
Sample volume for selection:	20–200 mL
Final cell product volume:	100 mL
Process time:	12–15 days


Material required

CliniMACS® Materials	Amount required
CliniMACS Prodigy	1 unit
CliniMACS Prodigy TS 520	1 piece
CliniMACS PBS/EDTA Buffer	1×3 L
CliniMACS PBS/EDTA Buffer	1×1 L
CliniMACS CD137 GMP Biotin	1 vial
CliniMACS Anti-Biotin GMP MicroBeads	1 vial
TexMACS™ GMP Medium (2 L bag)	~3×2 L bag
MACS® GMP CD3 pure	1 vial
MACS GMP Recombinant Human IL-2 (500 µg)	~4–8 vials
MACS GMP Vectofusin®-1	Variable


Additional materials	Amount required
Luer/Spike Interconnector	Variable
Triple sampling adapter	Variable
20 mL Reagent Bag	1–2 pieces
Human serum albumin (HSA)	Variable
Human AB serum	Variable
Sterile water for injection	Variable
Viral vector	Variable
Formulation solution	Variable
150 mL Transfer Bags	Variable
Syringes	Variable
Uninterruptable power supply	Presumed on site
CO ₂ and compressed air supply	Presumed on site
Sterile tubing welder	Presumed on site
Device to measure glucose and lactate levels	Presumed on site
Flow cytometer, e.g., MACSQuant® Analyzer 10 / Cell counter	Presumed on site
X-ray device for preparation of feeder cells	Presumed on site



Process overview



CliniMACS Prodigy TS 520 setup for the Tumor Reactive T Cell Process



Performance data

Starting product	Starting product CD137 ⁺ labeled cells (%)	Isolated CD137 ⁺ cells (%)	Recovery of CD137 ⁺ cells (%)	CD3 ⁺ T cells (%)	CD4 ⁺ /CD8 ⁺ T cells (%)	Viability (%)	Fold expansion	T cell number (×10 ⁶)
MEL 1	20.1	95.3	58.1	98.4	25.1 / 73.1	98.8	80,556	1,450
MEL 2	23.8	97.1	41.3	73.8	40.0 / 16.3	96.8	131	2.63
LP 3	4.9	89.2	22.2	97.2	37.8 / 56.3	99.3	5,300	5,300
LP 4	7.6	88.7	36.7	98.2	18.9 / 74.7	98.8	3,769	5,676

Table 1: Isolation of tumor-reactive T cells derived from patient material (frozen melanoma digests, MEL) and healthy donor leukapheresis material stimulated with peptides (LP). In-house data.



Miltenyi Biotec



www.cytogenics.com.br

Miltenyi Biotec B.V. & Co. KG | Phone +49 2204 8306-0 | Fax +49 2204 85197 | macsde@miltenyi.com | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.

MACS GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval. CliniMACS GMP MicroBeads are for research use and *ex vivo* cell processing only. CliniMACS, CliniMACS Prodigy, MACS, MACSQuant, TexMACS, Vectofusin and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide.

Copyright © 2022 Miltenyi Biotec and/or its affiliates. All rights reserved.